{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:39:25Z","timestamp":1789735165434,"version":"4.0.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1097\/iio.0000000000000096","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T13:59:59Z","timestamp":1448546399000},"page":"51-67","source":"Crossref","is-referenced-by-count":17,"title":["Compressive Optic Neuropathy in Thyroid Eye Disease"],"prefix":"10.1097","volume":"56","author":[{"given":"Preeti","family":"Thyparampil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210126","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/eye.2012.284","article-title":"Acute thyroid eye disease (TED): principles of medical and surgical management.","volume":"27","author":"Verity","year":"2013","journal-title":"Eye (Lond)"},{"key":"R2-5-20210126","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/ICU.0b013e3283499446","article-title":"The pathophysiology of thyroid eye disease (TED): implications for immunotherapy.","volume":"22","author":"Gupta","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-5-20210126","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","article-title":"Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption.","volume":"45","author":"Pfeilschifter","year":"1996","journal-title":"Clin Endocrinol"},{"key":"R4-5-20210126","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":". Clinical features of Graves ophthalmopathy in an incidence cohort.","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"R5-5-20210126","first-page":"543","article-title":". Update on thyroid eye disease and management.","volume":"3","author":"Bothum","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"R6-5-20210126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":". Clinical activity score as a guide in the management of patients with Graves ophthalmopathy.","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R7-5-20210126","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","article-title":". Development of a disease specific quality of life questionnaire for patients with Graves ophthalmopathy: the GO-QOL.","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"R8-5-20210126","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/eop.10.31","article-title":". Thyroid eye disease: ocular treatment.","volume":"5","author":"Eichhorn","year":"2010","journal-title":"Expert Rev Ophthalmol"},{"key":"R10-5-20210126","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":". Ciclosporin andprednisone v. prednisone in treatment of Graves ophthalmopathy: a controlled, randomized and prospective study.","volume":"16","author":"Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"R11-5-20210126","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":". The effect of etanercept on Graves ophthalmopathy: a pilot study.","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye (Lond)"},{"key":"R12-5-20210126","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01676830590912562","article-title":"Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy.","volume":"24","author":"Durrani","year":"2005","journal-title":"Orbit"},{"key":"R13-5-20210126","first-page":"457","article-title":". Monoclonal anti-TNF-alpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy.","volume":"109","author":"Komorowski","year":"2007","journal-title":"Klin Oczna"},{"key":"R14-5-20210126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","article-title":". Rituximab for thyroid eye disease.","volume":"26","author":"Silkiss","year":"2010","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R15-5-20210126","first-page":"251","article-title":"Campi I, et al..","volume":"28","author":"Salvi","year":"2009","journal-title":"Rituximab in the treatment of thyroid eye disease: science fiction Orbit"},{"key":"R17-5-20210126","first-page":"e163","article-title":". Systemic adverse events following rituximab therapy in patients with Graves disease.","volume":"34","author":"El Fassi","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"R18-5-20210126","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":". Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves disease is mediated through the insulin-like growth factor I receptor pathway.","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"key":"R19-5-20210126","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":". Selenium and the course of mild Graves orbitopathy.","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"R20-5-20210126","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"MP, van Kempen-Harteveld ML, Garcia MB, et al.. Radiotherapy for Graves orbitopathy: randomised placebo-controlled study.","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"R21-5-20210126","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","article-title":". Randomized double-blind trial of prednisone versus radiotherapy in Graves ophthalmopathy.","volume":"342","author":"Prummel","year":"1993","journal-title":"Lancet"},{"key":"R22-5-20210126","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ophtha.2003.12.054","article-title":". Orbital irradiation for Graves ophthalmopathy: is it safe A long-term follow-up study.","volume":"111","author":"Wakelkamp","year":"2004","journal-title":"Ophthalmology"},{"key":"R23-5-20210126","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.otc.2006.01.004","article-title":"Endoscopic orbital and optic nerve decompression.","volume":"39","author":"Metson","year":"2006","journal-title":"Otolaryngol Clin N Am"}],"container-title":["International Ophthalmology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IIO.0000000000000096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:04:30Z","timestamp":1621886670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004397-201605610-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/iio.0000000000000096","relation":{},"ISSN":["0020-8167"],"issn-type":[{"value":"0020-8167","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}